JKJeffrey P. Krischer

Jeffrey P. Krischer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeffrey P. Krischer has a total of 502 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Thyroid autoimmunity and the subsequent development of islet and celiac autoimmunity in the TEDDY study

    by Joanna L Clasen, Berglind Jonsdottir, Kendra Vehik, Kristian F Lynch, Hemang M Parikh, Jaakko J Koskenniemi, Åke Lernmark, Daniel Agardh, William A Hagopian, Marian J Rewers, et al.

    We aimed to determine if thyroid autoimmunity is associated with a child’s risk for subsequent development of islet or celiac autoantibodies. Children at high genetic risk of type 1 diabetes were followed for thyroid autoimmunity (thyroid peroxidase antibodies [TPOAb] and thyroglobulin antibodies [TGAb]), islet autoimmunity (IA), and celiac disease autoimmunity (CDA) in The Environmental Determinants of Diabetes in the Young study. Out of 5482 children tested for thyroid autoimmunity, IA, and CDA, 39% developed at least one autoantibody. At age 14 years, thyroid autoimmunity co-occurred with IA in 59 children (15 more cases than expected by chance alone, P = 0.02) and with CDA in 125 children (26 cases above expected, P = 0.01). The risk of developing IA or CDA after thyroid autoimmunity varied by which thyroid autoantibody appeared first: TPOAb-first was associated with both IA (HR 1.92, 95% CI, 1.09-3.40) and CDA (1.69, 95% CI, 1.03-2.76), whereas TGAb-first was not associated with the risk of either. Islet autoimmunity and CDA are frequently found in connection to thyroid autoimmunity in children and young adolescents. The relationships of thyroid autoimmunity with IA and CDA depend on which thyroid autoantibody appears first.


  • Phase I Clinical Trial of Islet Antigen–Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes

    by Carla J. Greenbaum, S. Alice Long, Stephen E. Gitelman, Jason L. Gaglia, Mark Daniels, Todd M. Brusko, Sandra Lord, Brian N. Bundy, Jeffrey P. Krischer, Michael J. Haller, et al.

    There is significant interest in antigen-specific approaches to delaying type 1 diabetes in preclinical stages and supporting tolerance after diagnosis. We conducted a phase I trial of a nonintegrating DNA plasmid constructed to secrete the type 1 diabetes antigen preproinsulin (PPI) and the immune modulatory cytokines transforming growth factor-β1 (TGF-β1), interleukin-10 (IL-10), and IL-2. In this placebo-controlled, double-masked study of 47 adults with stage 3 type 1 diabetes, we showed that the drug is safe and well tolerated, with most reported adverse events (AEs) categorized as grade 1 and with no clinically significant difference in AEs among treatment groups. There were no untoward metabolic or immune effects. We found pharmacodynamic evidence of treatment, as demonstrated by a dose-dependent type 1 interferon (IFN) signature. Plasmid DNA, representing a pharmocokinetic measure, was detected in the two highest dosing groups. We did not find global or antigen-specific immune cell changes following treatment with a DNA plasmid expressing PPI, IL-2, IL-10, and TGF-β1, and we did not detect immune changes driven by IL-2, IL-10, or TGF-β1. Our results support further trials of this novel tolerizing antigen construct. Article Highlights: Antigen-specific therapy is needed to induce tolerance in type 1 diabetes at early disease stages or in combination with immunotherapy. We conducted a phase I trial in type 1 diabetes of a novel plasmid construct expressing the islet antigen preproinsulin (PPI) and immunomodulatory cytokines transforming growth factor-β1 (TGF-β1), interleukin-10 (IL-10), and IL-2. The therapy was safe and well tolerated. Dose-dependent changes in DNA plasmid levels and type 1 interferon signatures were detected; however, global and antigen-specific immune changes to PPI, IL-2, IL-10, or TGF-β1 were not observed. Further trials are needed to assess efficacy.


  • Open Access

    Family history of type 2 diabetes delays development of type 1 diabetes in TEDDY children with islet autoimmunity

    by Riitta Veijola, Roy N. Tamura, Joanna L. Clasen, Helena Elding Larsson, Katharina Warncke, Andrea K. Steck, Michael J. Haller, Berglind Jonsdottir, Beena Akolkar, William A. Hagopian, et al.

    Aims/hypothesis: The aetiology of type 1 diabetes remains elusive. Family history of type 1 diabetes increases the disease risk but the role of other autoimmune diseases or type 2 diabetes in the family are unclear. Here, we aimed to analyse the effect of family history of diabetes and autoimmune diseases on development of islet autoimmunity and progression to type 1 diabetes. Methods: The Environmental Determinants of Diabetes in the Young (TEDDY) study is a prospective observational cohort study of children recruited as newborns in 2004–2010 at clinical centres in Finland, Germany, Sweden and the USA. A total of 8676 children with high-risk HLA-DR-DQ genotype for type 1 diabetes fulfilled the eligibility criteria for regular follow-up. Questionnaire-based family history of all types of diabetes and autoimmune diseases among first- and second-degree relatives (FDRs and SDRs; data available for 8558 and 7479 children, respectively) was collected. The main outcomes were development of islet autoimmunity and progression from autoimmunity to type 1 diabetes. Data until 31 January 2016 were analysed. Results: Persistent islet autoantibodies were found in 669 children and type 1 diabetes in 233 children (45% and 46% female sex, respectively). The median follow-up time after seroconversion was 6.5 years (IQR 3.3–8.5). Having an FDR with type 1 diabetes increased the child’s risk of islet autoimmunity (HR 2.2 [95% CI 1.8, 2.8]; p p =0.017). Notably, progression from autoantibody positivity to type 1 diabetes was significantly delayed in children having type 2 diabetes in an SDR (HR 0.61 [95% CI 0.44, 0.86]; p =0.004). Islet autoimmunity or progression to type 1 diabetes were not associated with other types of diabetes or autoimmune diseases in the family. Conclusions/interpretation: Family history of diabetes is differentially associated with development of islet autoimmunity and progression to type 1 diabetes. The contribution made by familial, genetic and environmental factors to the two phases of the disease pathogenesis deserves distinct analyses. Data availability: Data reported here can be obtained by request at the NIDDK Central Repository website, Resources for Research (R4R), https://repository.niddk.nih.gov/ . Graphical


  • Genetic Risk and Transition Through Preclinical Stages of Type 1 Diabetes

    by Andrea K Steck, Hemang M Parikh, Taylor M Triolo, Lauric Ferrat, Lu You, Peter A Gottlieb, Richard A Oram, Suna Onengut-Gumuscu, Jeffrey P Krischer, Stephen S Rich, et al.

    Context: The influence of genetic factors on the transition through preclinical stages of type 1 diabetes (T1D) has not been studied. Objective: Our aim was to evaluate the influence of genetic factors on transition through T1D stages. Methods: In TrialNet participants who have been genotyped with the TEDDY-T1DExomeChip array (Illumina HumanCoreExome Beadarray with custom content), we evaluated the influence of the overall T1D genetic risk score (GRS2), its human leukocyte antigen (HLA) and non-HLA components, HLA-DR3 and HLA-DR4 haplotypes, and 90 single-nucleotide variations previously associated with islet autoimmunity and/or T1D on 3 transitions between diabetes stages: from single confirmed autoantibody positive to stage 1 (N = 4314), from stage 1 to stage 2 (N = 3066), and from stage 2 to stage 3 (clinical) T1D (N = 2045). Results: The T1D GRS2 was associated with all 3 transitions with hazard ratios (HRs) of 1.11 (1.09-1.14) for single-autoantibody positivity to stage 1, HR 1.05 (1.03-1.08) for stage 1 to 2, and HR 1.13 (1.09-1.17) for stage 2 to 3 T1D. The T1D GRS2 HLA and HLA class II components were associated with all 3 transitions. The HLA class I component and the HLA-DR4 haplotype were associated with the transition from single-autoantibody positivity to stage 1 and from stage 2 to stage 3 T1D, while HLA-DR3 was associated only with the latter. Conclusion: Genetics influence transitions through each stage of preclinical T1D, with main contributions from HLA class II. These results increase our understanding of T1D development and support incorporating the T1D GRS2 to enhance the prediction of progression through the preclinical stages of T1D.


  • Open Access

    Type 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter

    by Lauric A. Ferrat, Erin L. Templeman, Andrea K. Steck, Hemang M. Parikh, Lu You, Suna Onengut-Gumuscu, Peter A. Gottlieb, Taylor M. Triolo, Stephen S. Rich, Jeffrey Krischer, et al.

    Aims/hypothesis: Efficient prediction of clinical type 1 diabetes is important for risk stratification and monitoring of autoantibody-positive individuals. In this study, we compared type 1 diabetes predictive models for predictive performance, cost and participant time needed for testing. Methods: We developed 1943 predictive models using a Cox model based on a type 1 diabetes genetic risk score (GRS2), autoantibody count and types, BMI, age, self-reported gender and OGTT-derived glucose and C-peptide measures. We trained and validated the models using halves of a dataset comprising autoantibody-positive first-degree relatives of individuals with type 1 diabetes (n=3967, 49% female, 14.9 ± 12.1 years of age) from the TrialNet Pathway to Prevention study. The median duration of follow-up was 4.7 years (IQR 2.0–8.1), and 1311 participants developed clinical type 1 diabetes. Models were compared for predictive performances, estimated cost and participant time. Results: Models that included metabolic measures had best performance, with most exhibiting small performance differences (less than 3% and p>0.05). However, the cost and participant time associated with measuring metabolic variables ranged between US$56 and US$293 and 10–165 min, respectively. The predictive model performance had temporal variability, with the highest GRS2 influence and discriminative power being exhibited in the earliest preclinical stages. OGTT-derived metabolic measures had a similar performance to HbA1c- or Index60-derived models, with an important difference in cost and participant time. Conclusions/interpretation: Cost–performance model analyses identified trade-offs between cost and performance models, and identified cost-minimising options to tailor risk-screening strategies. Graphical


  • Comparative Analysis of the Sensitivity, Specificity, Concordance, and 5-Year Predictive Power of Diabetes-Related Autoantibody Assays

    by Jeffrey P. Krischer, Sarah Muller, Lu You, Peter Achenbach, Elena Bazzigaluppi, Cristina Brigatti, Vito Lampasona, Anu Mathew, Peter Robinson, David Seftel, et al.

    This study compares novel type 1 diabetes–related autoantibody assays developed to improve upon the standard radiobinding assay (RBA). Samples from 1,505 individuals, followed for 5 years or to clinical type 1 diabetes, originally tested by RBA were aliquoted and sent blindly to five laboratories (Barbara Davis Diabetes Center [BDC], Institute of Diabetes Research [IDR], Diabetes Research Institute [DRI], Meso Scale Discovery [MSD], and Enable Biosciences) to be tested by electrochemiluminescence (ECL) assays, Luciferase Immuno Precipitation System (LIPS) assays, multiplex antibody detection by agglutination-PCR (ADAP) assays, and N-terminally truncated GAD65 or IA2β autoantibody RBAs (tGADA/IA2βA). The fraction of samples that were concordant for negative/positive interpretations across all assays were 79.7% (GADA), 65.2% (tyrosine phosphatase-related insulinoma antigen 2 [IA-2A]), 36.2% (insulin autoantibodies [IAA]), and 67.5% (zinc transporter 8 [ZnT8A]). The assays with the highest Youden J index for predicting the previous RBA results differed by autoantibody: 0.65 LIPS (IDR) for IAA, 0.91 ECL (BDC) for ZnT8A, 0.82 tGADA RBA (IDR) for GADA, 0.91 ECL (MSD and BDC) for IA-2A. The Youden J index for predicting 5-year type 1 diabetes varied significantly across assays and was highest for LIPS (DRI) for all autoantibody combinations, with little variation in the respective maximum Youden J index. The discordance between assays makes it problematic to interpret positivity when comparing results from different assays. Longitudinal autoantibody assessments should be tested with the same assay. ARTICLE HIGHLIGHTS: Interassay concordance and 5-year diabetes prediction of islet cell autoantibody detection using the radiobinding assay (TrialNet), two independently developed multiplex electrochemiluminescence detection methods, the luciferase immune precipitation system, detection by agglutination-PCR, and truncated GADA, and IA2βA radiobinding assays are reported. There was considerable discordance that varied by type of autoantibody across the assays. Type 1 diabetes prediction was relatively high and uniform, implying confirmation of increased diabetes risk among those who are multiple autoantibody positive, although substantial false positive rates need to be considered when autoantibodies alone are used for screening to identify high diabetes risk.


  • Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis

    by Lu You, Lauric A. Ferrat, Richard A. Oram, Hemang M. Parikh, Andrea K. Steck, Jeffrey Krischer, Maria J. Redondo

    Aims/hypothesis Although statistical models for predicting type 1 diabetes risk have been developed, approaches that reveal the heterogeneity of the at-risk population by identifying clinically meaningful clusters are lacking. We aimed to identify and characterise clusters of islet autoantibody-positive individuals who share similar characteristics and type 1 diabetes risk. Methods We tested a novel outcome-guided clustering method in initially non-diabetic autoantibody-positive relatives of individuals with type 1 diabetes, using the TrialNet Pathway to Prevention study data (n=1123). The outcome of the analysis was the time to development of type 1 diabetes, and variables in the model included demographic characteristics, genetics, metabolic factors and islet autoantibodies. An independent dataset (the Diabetes Prevention Trial of Type 1 Diabetes Study) (n=706) was used for validation. Results The analysis revealed six clusters with varying type 1 diabetes risks, categorised into three groups based on the hierarchy of clusters. Group A comprised one cluster with high glucose levels (median for glucose mean AUC 9.48 mmol/l; IQR 9.16–10.02) and high risk (2-year diabetes-free survival probability 0.42; 95% CI 0.34, 0.51). Group B comprised one cluster with high IA-2A titres (median 287 DK units/ml; IQR 250–319) and elevated autoantibody titres (2-year diabetes-free survival probability 0.73; 95% CI 0.67, 0.80). Group C comprised four lower-risk clusters with lower autoantibody titres and glucose levels (with 2-year diabetes-free survival probability ranging from 0.84–0.99 in the four clusters). Within group C, the clusters exhibit variations in characteristics such as glucose levels, C-peptide levels and age. A decision rule for assigning individuals to clusters was developed. Use of the validation dataset confirmed that the clusters can identify individuals with similar characteristics. Conclusions/interpretation Demographic, metabolic, immunological and genetic markers may be used to identify clusters of distinctive characteristics and different risks of progression to type 1 diabetes among autoantibody-positive individuals with a family history of type 1 diabetes. The results also revealed the heterogeneity in the population and complex interactions between variables. Graphical Abstract


  • Open Access

    Caesarean section and risk of type 1 diabetes

    by Tarini Singh, Andreas Weiss, Kendra Vehik, Jeffrey Krischer, Marian Rewers, Jorma Toppari, Åke Lernmark, William Hagopian, Beena Akolkar, Ezio Bonifacio, et al.

    Aims/hypothesis: Delivery by Caesarean section continues to rise globally and has been associated with the risk of developing type 1 diabetes and the rate of progression from pre-symptomatic stage 1 or 2 type 1 diabetes to symptomatic stage 3 disease. The aim of this study was to examine the association between Caesarean delivery and progression to stage 3 type 1 diabetes in children with pre-symptomatic early-stage type 1 diabetes. Methods: Caesarean section was examined in 8135 children from the TEDDY study who had an increased genetic risk for type 1 diabetes and were followed from birth for the development of islet autoantibodies and type 1 diabetes. Results: The likelihood of delivery by Caesarean section was higher in children born to mothers with type 1 diabetes (adjusted OR 4.61, 95% CI 3.60, 5.90, pppp28–33 years: adjusted OR 1.19, 95% CI 1.04, 1.35, p=0.01; age group >33 years: adjusted OR 1.80, 95% CI 1.58, 2.06, pp=0.07). Delivery by Caesarean section was associated with a modestly increased rate of progression to stage 3 type 1 diabetes in children who had developed multiple islet autoantibody-positive pre-symptomatic early-stage type 1 diabetes (adjusted HR 1.36, 95% CI 1.03, 1.79, p=0.02). No interaction was observed between Caesarean section and non-HLA SNPs conferring susceptibility for type 1 diabetes. Conclusions/interpretation: Caesarean section increased the rate of progression to stage 3 type 1 diabetes in children with pre-symptomatic early-stage type 1 diabetes. Data availability: Data from the TEDDY study (https://doi.org/10.58020/y3jk-x087) reported here will be made available for request at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository (NIDDK-CR) Resources for Research (R4R) (https://repository.niddk.nih.gov/). Graphical


  • Open Access

    The Influence of Pubertal Development on Autoantibody Appearance and Progression to Type 1 Diabetes in the TEDDY Study

    by Katharina Warncke, Roy Tamura, Desmond A Schatz, Riitta Veijola, Andrea K Steck, Beena Akolkar, William Hagopian, Jeffrey P Krischer, Åke Lernmark, Marian J Rewers, et al.

    Context The 2 peaks of type 1 diabetes incidence occur during early childhood and puberty. Objective We sought to better understand the relationship between puberty, islet autoimmunity, and type 1 diabetes. Methods The relationships between puberty, islet autoimmunity, and progression to type 1 diabetes were investigated prospectively in children followed in The Environmental Determinants of Diabetes in the Young (TEDDY) study. Onset of puberty was determined by subject self-assessment of Tanner stages. Associations between speed of pubertal progression, pubertal growth, weight gain, homeostasis model assessment of insulin resistance (HOMA-IR), islet autoimmunity, and progression to type 1 diabetes were assessed. The influence of individual factors was analyzed using Cox proportional hazard ratios. Results Out of 5677 children who were still in the study at age 8 years, 95% reported at least 1 Tanner Stage score and were included in the study. Children at puberty (Tanner Stage ≥2) had a lower risk (HR 0.65, 95% CI 0.45-0.93; P = .019) for incident autoimmunity than prepubertal children (Tanner Stage 1). An increase of body mass index Z-score was associated with a higher risk (HR 2.88, 95% CI 1.61-5.15; P < .001) of incident insulin autoantibodies. In children with multiple autoantibodies, neither HOMA-IR nor rate of progression to Tanner Stage 4 were associated with progression to type 1 diabetes. Conclusion Rapid weight gain during puberty is associated with development of islet autoimmunity. Puberty itself had no significant influence on the appearance of autoantibodies or type 1 diabetes. Further studies are needed to better understand the underlying mechanisms.


  • Genetic Associations With C-peptide Levels Before Type 1 Diabetes Diagnosis in At-risk Relatives

    by Taylor M Triolo, Hemang M Parikh, Mustafa Tosur, Lauric A Ferrat, Lu You, Peter A Gottlieb, Richard A Oram, Suna Onengut-Gumuscu, Jeffrey P Krischer, Stephen S Rich, et al.

    Objective We sought to determine whether the type 1 diabetes genetic risk score-2 (T1D-GRS2) and single nucleotide polymorphisms (SNPs) are associated with C-peptide preservation before type 1 diabetes diagnosis. Methods We conducted a retrospective analysis of 713 autoantibody-positive participants who developed type 1 diabetes in the TrialNet Pathway to Prevention Study who had T1DExomeChip data. We evaluated the relationships of 16 known SNPs and T1D-GRS2 with area under the curve (AUC) C-peptide levels during oral glucose tolerance tests conducted in the 9 months before diagnosis. Results Higher T1D-GRS2 was associated with lower C-peptide AUC in the 9 months before diagnosis in univariate (β=-0.06, PP=0.005) analyses. Participants with the JAZF1 rs864745 T allele had lower C-peptide AUC in both univariate (β=-0.11, P=0.002) and multivariate (β=-0.06, P=0.018) analyses. Conclusions The type 2 diabetes-associated JAZF1 rs864745 T allele and higher T1D-GRS2 are associated with lower C-peptide AUC prior to diagnosis of type 1 diabetes, with implications for the design of prevention trials.